Miwanda, B; Moore, S; Muyembe, J.-, J; Nguefack-Tsague, G; Kabangwa, IK; Ndjakani, DY; Mutreja, A; Thomson, N; Thèfenne, H; Garnotel, E; Tshapenda, G; Kakongo, DK; Kalambayi, G; Piarroux, R (2015) Antimicrobial Drug Resistance of Vibrio cholerae, Democratic Republic of the Congo. Emerging infectious diseases, 21 (5). pp. 847-851. ISSN 1080-6040 DOI: https://doi.org/10.3201/eid2105.141233

Downloaded from: http://researchonline.lshtm.ac.uk/2197131/

DOI: 10.3201/eid2105.141233

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Antimicrobial Drug Resistance of *Vibrio cholerae,* Democratic Republic of the Congo

Berthe Miwanda, Sandra Moore, Jean-Jacques Muyembe, Georges Nguefack-Tsague, Ickel Kakongo Kabangwa, Daniel Yassa Ndjakani, Ankur Mutreja, Nicholas Thomson, Helene Thefenne, Eric Garnotel, Gaston Tshapenda, Denis Kandolo Kakongo, Guy Kalambayi, Renaud Piarroux

We analyzed 1,093 *Vibrio cholerae* isolates from the Democratic Republic of the Congo during 1997–2012 and found increasing antimicrobial drug resistance over time. Our study also demonstrated that the 2011–2012 epidemic was caused by an El Tor variant clonal complex with a single antimicrobial drug susceptibility profile.

Cholera is an acute intestinal infection caused by *Vibrio cholerae* (1). Although hydration remains the primary treatment for cholera, antimicrobial drug therapy is recommended for severely ill patients (2). However, multidrug-resistant *V. cholerae* strains have long been observed in Africa (3), and strains exhibiting new resistance phenotypes have emerged during recent epidemics (4). It is therefore critical to carefully monitor changes in strains’ susceptibility to antimicrobial drugs in each African country and adapt treatment recommendations accordingly.

Few longitudinal studies assessing shifts in the resistance of *V. cholerae* to antimicrobial drugs in Africa have been established. The available studies are limited either to a restricted area (5) or a short time period (6). We describe the long-term evolution of antimicrobial drug susceptibility of an extensive set of *V. cholerae* isolates collected in the Democratic Republic of the Congo (DRC). We applied whole-genome sequencing and multiple locus variable-number tandem-repeat analysis (MLVA) to clarify the mechanisms behind the aggressive epidemic of 2011–2012 that spread throughout the country, affecting regions to which cholera was not endemic (7).

**The Study**

Sample collection included all available isolates from major outbreaks in the DRC during 1997–2012, which were stored at the National Institute of Biomedical Research. The Table shows the locations where the 1,093 tested isolates were collected.

*V. cholerae* O1 strains stored in nutrient agar during 1997–2012 were cultured on thiosulfate citrate bile salt agar and nutrient agar at the National Laboratory, Kinshasa, DRC. The strains were enriched in alkaline peptone water liquid medium and incubated at 37°C for 18–24 h. Biochemical and serogroup characterization was subsequently performed according to standard protocols (8).

Antimicrobial drug susceptibility testing of 1,093 confirmed *V. cholerae* isolates was performed by using the Kirby-Bauer disk diffusion method (9) with Mueller agar (bioMérieux, Marcy l’Étoile, France). *V. cholerae* O1 Ogawa and Inaba reference strains (ATCC) served as controls. Isolates were tested against 9 antimicrobial drugs as follows: ampicillin (10 µg), chloramphenicol (30 µg), sulfamethoxazole/trimethoprim (1.25 + 23.75 µg), tetracycline (30 µg), doxycycline (30 µg), norfloxacin (5 µg), ciprofloxacin (5 µg), nalidixic acid (30 µg), and erythromycin (30 µg) (bioMérieux). Interpretation of inhibition diameters (sensitive, intermediate, and resistant) was performed according to Clinical and Laboratory Standards Institute guidelines (10). When no interpretive criteria for *V. cholerae* were available from these guidelines, breakpoints for *Enterobacteriaceae* were applied by using *Escherichia coli* ATCC 25922 for quality control. The few intermediate results were categorized as resistant for this study. The strains were then regrouped into 21 resistance profiles.

Seventy-four clinical isolates from the 2011–2012 epidemic, spatiotemporally representative of outbreak diffusion, were subcultured and transported to Marseille, France. In Marseille, the strains were recultivated and identified as previously described (11). For DNA extraction, a 50-colony aliquot of cultured cells was suspended in 500
DISPATCHES

Table. Distribution of 1,093 Vibrio cholerae isolates, by year and province, Democratic Republic of the Congo, 1997–2012

| Year | Bandundu | Bas-Congo | Equateur | Kasai-Oriental | Katanga | Kinshasa | Maniema | North Kivu | Oriental | South Kivu | Total |
|------|----------|-----------|----------|---------------|---------|----------|---------|------------|----------|------------|-------|
| 1997 | 0        | 4         | 0        | 0             | 2       | 0        | 0       | 0          | 0        | 0          | 6     |
| 1998 | 0        | 2         | 0        | 0             | 15      | 14       | 0       | 4          | 7        | 0          | 42    |
| 1999 | 8        | 0         | 0        | 0             | 1       | 22       | 0       | 0          | 0        | 0          | 31    |
| 2000 | 3        | 0         | 10       | 0             | 0       | 13       | 0       | 0          | 0        | 0          | 26    |
| 2001 | 0        | 0         | 0        | 0             | 16      | 0        | 0       | 0          | 0        | 0          | 16    |
| 2002 | 0        | 0         | 0        | 0             | 44      | 0        | 0       | 0          | 0        | 0          | 44    |
| 2003 | 0        | 0         | 0        | 19            | 21      | 4        | 0       | 0          | 0        | 0          | 44    |
| 2004 | 0        | 0         | 0        | 0             | 1       | 2        | 0       | 3          | 0        | 0          | 6     |
| 2005 | 0        | 0         | 0        | 0             | 1       | 0        | 0       | 2          | 0        | 0          | 3     |
| 2006 | 2        | 3         | 0        | 0             | 9       | 0        | 0       | 0          | 0        | 0          | 14    |
| 2007 | 0        | 0         | 0        | 0             | 15      | 1        | 0       | 1          | 5        | 0          | 22    |
| 2008 | 0        | 0         | 0        | 0             | 30      | 0        | 5       | 4          | 17       | 0          | 56    |
| 2009 | 0        | 0         | 0        | 0             | 112     | 0        | 0       | 2          | 0        | 11         | 125   |
| 2010 | 0        | 0         | 0        | 0             | 10      | 0        | 0       | 0          | 0        | 5          | 15    |
| 2011 | 46       | 0         | 17       | 0             | 0       | 73       | 4       | 151        | 45       | 0          | 336   |
| 2012 | 11       | 25        | 16       | 0             | 1       | 27       | 0       | 196        | 31       | 0          | 307   |
| Total| 70       | 34        | 43       | 19            | 276     | 158      | 9       | 363        | 105      | 16         | 1,093 |

µL NucliSENS easyMAG lysis buffer (bioMérieux). DNA was extracted by using a NucliSENS easyMAG platform (bioMérieux) according to the manufacturer’s instructions. MLVA-based genotyping of the V. cholerae isolates and eBURST analysis (http://eBURST.mlst.net) were performed as previously described (11). To perform a phylogenetic assessment of the core V. cholerae genome on the basis of genome-wide single nucleotide polymorphisms, whole-genome sequencing was performed on an isolate (L286) collected at epidemic onset by using a HiSeq Illumina System (Illumina, San Diego, CA, USA) as previously described (12).

A spatiotemporal analysis was performed on the basis of the antibiogram profiles of V. cholerae isolates collected in the DRC during 1997–2012. The strain profiles were plotted by year (Figure 1) and then mapped by year and province. Using these data, we regrouped them into 5 representative periods (Figure 2). The V. cholerae strains displayed an increasingly complex resistance phenotype to various antimicrobials. Sulfamethoxazole/trimethoprim resistance was observed initially, followed by resistance to nalidixic acid, erythromycin, and chloramphenicol during the early 2000s. Although sensitivity to fluoroquinolones seemed to be preserved, strain resistance patterns continued to evolve with the circulation of isolates resistant to tetracyclines and ampicillin from 2007–2010. Finally, isolates collected during 2011–2012, which was marked by the westward spread of a major epidemic (7), displayed a single antimicrobial drug susceptibility profile: resistance to most antimicrobial drugs except cyclines and fluoroquinolones.

Serotype analysis of the 1,093 V. cholerae isolates showed that Inaba strains were restricted to the western region of the country, Ogawa strains were isolated in the east and south, and Hikojima strains were restricted to Oriental Province, in the northeastern region of the country. During 2001–2010, Inaba and Ogawa serotypes were observed, but Ogawa predominated; during 2011–2012, these serotypes switched, and the Ogawa serotype was almost completely replaced by Inaba.

To examine the particular 2011–2012 epidemic that spread throughout the DRC (7), 74 V. cholerae isolates were assessed by using MLVA and eBURST analysis. Overall, the isolates displayed 19 different MLVA genotypes, of which 18 grouped into 1 clonal complex. eBURST analysis indicated that the clonal complex likely arose from a founder strain identified at the beginning of the epidemic. Furthermore, whole-genome sequence analysis of an isolate identified in March 2011 in Lubunga, Oriental Province (L286), revealed that the strain was an El Tor variant with CTX-3 type phage and a RS1 satellite phage. Phylogeny analysis situated this DRC strain close to the major Kenyan clade in the most recent wave of the seventh pandemic (data not shown).

Conclusions

Analysis of a panel of V. cholerae clinical isolates from the DRC from 1997–2012 highlighted a loss of sensitivity to leading antimicrobial drugs, although strains remain susceptible to fluoroquinolones. However, a risk for emergence and spread of fluoroquinolone-resistant strains exists, as has been shown elsewhere in Africa (13). Because resistance to nalidixic acid is frequently associated with decreased susceptibility to fluoroquinolones, nalidixic acid resistance must be detected to monitor the emergence of highly resistant strains (14).

Our findings also provide new insight regarding the cholera epidemic of 2011–2012. This epidemic appears to have been caused by the expansion of a specific V. cholerae subpopulation, which rapidly diffused country-
Drug Resistance of *V. cholerae*, DRC

Furthermore, sequence analysis showed that the clone responsible for this epidemic, an El Tor variant with CTX-3 type phage, falls close to the major Kenyan clade in wave 3 of the seventh pandemic. This observation correlates with a 2011 study demonstrating that the seventh cholera pandemic had been caused by specific strains originating from a unique ancestral clone that have spread globally in successive waves (12). The 2011–2012 isolates displayed a specific antimicrobial drug resistance pattern, characterized by the return of tetracycline and doxycycline sensitivity. The outbreak strain also represented a serotype switch from Ogawa to Inaba. However, further MLVA genotyping of preoutbreak isolates is required to determine whether these strains were already present in the region or if they represent a new *V. cholerae* population.

This study demonstrates that molecular and microbiological analyses of *V. cholerae* isolates provide extensive insight into the mechanisms of cholera epidemics. MLVA and whole-genome sequencing are powerful tools for elucidating epidemic dynamics because these methods have been used to link distinct outbreaks and identify the origin of certain epidemic *V. cholerae* strains (15). Improved sampling of clinical isolates is essential to monitor changes in pathogen antimicrobial drug resistance and elucidate the dissemination pathways of toxigenic strains to ensure proper management of patients requiring antimicrobial drug treatment and to appropriately direct the public health response.

**Acknowledgments**

We thank Benoit Kebela Ilunga and Vital Mondonge Makuma for authorizing access to data and sharing their expertise. François-Xavier Mbopi-Kéou, Ditu Kazambu, Dieulla Delissaint, and Louis Koyange Delysogo assisted with the collection of *V. cholerae* isolates. We also thank the health authorities of the Provincial Directorates and the DRC health zone teams for authorizing and supporting the study.
The collection of strains and biological analyses were supported by many partners, including the World Health Organization, the Veolia Foundation, and the African Cholera Surveillance Network. Epidemiologic surveillance was financially supported by the World Health Organization, Epicentre, and the Belgian Development Cooperation.

Ms. Miwanda is a biologist specializing in the diagnosis of bacterial diseases of epidemic potential and head of the Surveillance des Maladies à Potentiel Epidémique unit at the DRC Public Health National Laboratory. She is responsible for the diagnosis of meningitis, cholera, plague, and bloody diarrhea.

References
1. Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 2004;363:223–33. http://dx.doi.org/10.1016/S0140-6736(03)15328-7
2. Centers for Disease Control and Prevention. *Vibrio cholerae* infection: antibiotic treatment. Recommendations for the use of antibiotics for the treatment of cholera. Atlanta: The Centers; 2013 [cited 2013 Aug 5]. http://www.cdc.gov/cholera/treatment/antibiotic-treatment.html
3. Finch MJ, Morris JG Jr, Kaviti J, Kagwanja W, Levine MM. Epidemiology of antimicrobial resistant cholera in Kenya and East Africa. Am J Trop Med Hyg. 1988;39:484–90.
4. Ngandjio A, Tejiokem M, Wouafo M, Ndome I, Yonga M, Guenole A, et al. Antimicrobial resistance and molecular characterization of *Vibrio cholerae* O1 during the 2004 and 2005 outbreak of cholera in Cameroon. Foodborne Pathog Dis. 2009;6:49–56. http://dx.doi.org/10.1089/fpd.2008.0127
5. Mandomando I, Espasa M, Vallès X, Sacarlal J, Sigaúque B, Ruiz J, et al. Antimicrobial resistance of *Vibrio cholerae* O1 serotype Ogawa isolated in Manhiça District Hospital, southern Mozambique. J Antimicrob Chemother. 2007;60:662–4. Epub 2007 Jul 11. http://dx.doi.org/10.1093/jac/dkm257
6. Materu SF, Lema OE, Mukanza HM, Adhiambo CG, Carter JY. Antibiotic resistance pattern of *Vibrio cholerae* and *Shigella* causing diarrhoea outbreaks in the eastern Africa region: 1994–1996. East Afr Med J. 1997;74:193–7.
7. Bompangue D, Vesenbeck SM, Giraudoux P, Castro M, Muyembe JJ, Kebela Ilunga B, et al. Cholera ante portas—the re-emergence of cholera in Kinshasa after a ten-year hiatus. PLoS Curr. 2012;4:RRN1310.
8. Centers for Disease Control and Prevention. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta: The Centers; 1999 [cited 2013 Apr 28]. http://www.cdc.gov/cholera/pdf/Laboratory-Methods-for-the-Diagnosis-of-Epidemic-Dysentery-and-Cholera.pdf

9. Jorgensen JH, Turnidge JD. Susceptibility test methods: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. 9th ed. Washington (DC): ASM Press; 2007. p. 1152–72.

10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standard. 9th edition. Clinical and Laboratory Standards Institute document M2–A9. Wayne (PA): The Institute; 2006.

11. Rebaudet S, Mengel MA, Koivogui L, Moore S, Mutreja A, Kande Y, et al. Deciphering the origin of the 2012 cholera epidemic in Guinea by integrating epidemiological and molecular analyses. PLoS Negl Trop Dis. 2014;8:e2898. http://dx.doi.org/10.1371/journal.pntd.0002898

12. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature. 2011;477:462–5. http://dx.doi.org/10.1038/nature10392

13. Islam MS, Midzi SM, Charimiari L, Cravioto A, Endtz HP. Susceptibility to fluoroquinolones of Vibrio cholerae O1 isolated from diarrheal patients in Zimbabwe. JAMA. 2009;302:2321–2. http://dx.doi.org/10.1001/jama.2009.1750

14. Ray P, Sharma J, Marak R, Garg RK. Predictive efficacy of nalidixic acid resistance as a marker of fluoroquinolone resistance in Salmonella enterica var Typhi. Indian J Med Res. 2006;124:105–8.

15. Hendriksen RS, Price LB, Schupp JM, Gillee JD, Kaas RS, Engelthaler DM, et al. Population genetics of Vibrio cholerae from Nepal in 2010: evidence on the origin of the Haitian outbreak. MBio. 2011;2:e00157–11. http://dx.doi.org/10.1128/mBio.00157-11

Address for correspondence: Renaud Piarroux, APHM–Hôpital de la Timone, Laboratoire de Parasitologie-Mycologie, 264 rue Saint Pierre, 13385 Marseille CEDEX 05, France; e-mail: renaud.piarroux@ap-hm.fr

November 2014: Foodborne Infections

Including:

- Blastomycosis Mortality Rates, United States, 1990–2010
- Legionnaires’ Disease Incidence and Risk Factors, New York, New York, USA, 2002–2011
- Death Patterns during the 1918 Influenza Pandemic in Chile
- Genomic Definition of Hypervirulent and Multidrug-Resistant Klebsiella pneumoniae Clonal Groups
- Respiratory Viruses and Bacteria among Pilgrims during the 2013 Hajj
- Drug-Resistant Candida glabrata Infection in Cancer Patients
- Novel Chlamydia trachomatis Strains in Heterosexual Sex Partners, Indianapolis, Indiana, USA

http://wwwnc.cdc.gov/eid/articles/issue/20/11/table-of-contents